Evolent Health, Inc (NYSE:EVH) – Analysts at Leerink Swann reduced their Q3 2017 EPS estimates for Evolent Health in a note issued to investors on Tuesday. Leerink Swann analyst D. Larsen now anticipates that the technology company will post earnings of ($0.07) per share for the quarter, down from their previous estimate of ($0.05). Leerink Swann currently has a “Outperform” rating and a $32.00 target price on the stock. Leerink Swann also issued estimates for Evolent Health’s Q4 2017 earnings at ($0.05) EPS, FY2017 earnings at ($0.53) EPS and FY2018 earnings at $0.10 EPS.

EVH has been the topic of several other research reports. Zacks Investment Research lowered Evolent Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Jefferies Group LLC restated a “buy” rating and set a $28.00 target price on shares of Evolent Health in a research report on Thursday, April 13th. Cowen and Company restated an “outperform” rating and set a $35.00 target price on shares of Evolent Health in a research report on Wednesday, June 28th. BidaskClub lowered Evolent Health from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, ValuEngine lowered Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $29.90.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/11/q3-2017-eps-estimates-for-evolent-health-inc-evh-decreased-by-analyst.html.

Shares of Evolent Health (NYSE:EVH) opened at 17.65 on Friday. Evolent Health has a 52-week low of $14.50 and a 52-week high of $27.50. The stock’s 50 day moving average price is $24.94 and its 200-day moving average price is $22.68. The firm’s market cap is $1.16 billion.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The company had revenue of $107.30 million for the quarter, compared to analyst estimates of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. Evolent Health’s revenue was up 89.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.20) earnings per share.

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Evolent Health by 7.5% in the second quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock valued at $137,857,000 after buying an additional 379,185 shares during the period. FMR LLC increased its stake in shares of Evolent Health by 102.1% in the first quarter. FMR LLC now owns 4,531,523 shares of the technology company’s stock valued at $101,053,000 after buying an additional 2,289,227 shares during the period. Pennant Capital Management LLC increased its stake in shares of Evolent Health by 2.9% in the first quarter. Pennant Capital Management LLC now owns 2,843,021 shares of the technology company’s stock valued at $63,399,000 after buying an additional 81,300 shares during the period. Vanguard Group Inc. increased its stake in shares of Evolent Health by 18.1% in the first quarter. Vanguard Group Inc. now owns 2,531,928 shares of the technology company’s stock valued at $56,462,000 after buying an additional 388,668 shares during the period. Finally, Riverbridge Partners LLC bought a new stake in shares of Evolent Health during the second quarter valued at approximately $58,878,000. Institutional investors and hedge funds own 73.16% of the company’s stock.

In other Evolent Health news, COO Thomas Peterson III sold 83,108 shares of the stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $24.99, for a total value of $2,076,868.92. Following the transaction, the chief operating officer now owns 341,092 shares in the company, valued at $8,523,889.08. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Seth Blackley sold 15,000 shares of the stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the transaction, the president now owns 760,944 shares in the company, valued at approximately $19,023,600. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,153,967 shares of company stock worth $253,648,377. Corporate insiders own 8.79% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.